Herantis Pharma Oyj (HRPMF) Discusses Phase 1b Biomarker Data for HER-096 in Parkinson's Disease and Implications for Clinical Development Transcript

Core Insights - Herantis Pharma has announced significant biomarker data for HER-096, its lead asset for treating Parkinson's disease, indicating a biological response to dosing in humans [1][2] - The company aims to halt the progression of Parkinson's disease with HER-096, a small peptide that mimics the neurotrophic factor CDNF, protecting dopamine neurons and supporting their functional restoration [2] - Following the completion of the Phase I program, the company has established solid safety data, demonstrated efficient brain penetration, and now possesses proof of biological efficacy, which will aid in discussions with potential pharmaceutical partners and investors for a Phase II efficacy trial [3]